FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/논문
연구 도서관으로 돌아가기
PubMedReview

A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.

Min Jee Sun, Jo Seong Jun, Lee Sangyoung, Kim Duk Yeon, Kim Da Hyun, Lee Chae Bin, Bae Soo Kyung
Drug design, development and therapy2025DOI: 10.2147/DDDT.S506957
GLP-1 receptor agoniststirzepatideexenatideliraglutidedulaglutidesemaglutide

품질 점수

7/10

참조 문헌

0

피험자

비인간

Peptide Contacts 분석

Study Design

Review papers serve a critical role in synthesizing disparate findings into a coherent narrative. For rapidly evolving fields like peptide therapeutics, reviews help researchers and practitioners identify consensus and controversy.

Our Assessment

Quality Assessment: 7/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

The results for GLP-1 receptor agonists, tirzepatide, exenatide, liraglutide, dulaglutide, semaglutide are encouraging.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Strong methodology makes this a valuable addition to the GLP-1 receptor agonists, tirzepatide, exenatide, liraglutide, dulaglutide, semaglutide evidence base. The findings here should inform future clinical trial design.

주요 발견

The review comprehensively examines the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1/GIP receptor agonist, highlighting structural modifications that prolong half-life but may increase adverse event risk. It also notes significant changes in exposure for oral contraceptives and levothyroxine with tirzepatide and semaglutide.

제한 사항

The review is limited by the lack of clinical data on drug-metabolizing enzyme- and transporter-mediated DDIs, and a need for further investigation into alterations in volume of distribution and clearance due to other mechanisms of action.

이 연구를 어떻게 해석해야 하는지

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Reviews are only as good as the studies they include. Check whether the review examined study quality or simply tallied results.

4

Look for discussion of publication bias — studies with negative results are less likely to be published, which can skew review conclusions.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Peptide Contacts 분석

Highlighting the latest advancements and considerations for clinicians using GLP-1 receptor agonists and tirzepatide in treating type 2 diabetes and obesity.

GLP-1 receptor agoniststirzepatideexenatideliraglutidedulaglutidesemaglutide

GLP-1 Receptor Agonists: Advancements in Pharmacokinetics and Drug Interactions

Published: May 16, 2026 | Source: Drug design, development and therapy (2025) | Category: GLP-1 receptor agonists, tirzepatide, exenatide, liraglutide, dulaglutide, semaglutide

Overview

A recent comprehensive review published in Drug Design, Development and Therapy provides critical insights into the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists (GLP-1 RAs) and a dual GLP-1/GIP receptor agonist. This study highlights how structural modifications to these peptides extend their half-life but may also increase the risk of adverse events, impacting clinical use in treating type 2 diabetes and obesity.

Study Background

GLP-1 RAs were initially developed to treat type 2 diabetes by mimicking the effects of natural GLP-1. However, native human GLP-1 has a very short half-life (approximately 2 minutes), necessitating structural modifications such as amino acid sequence changes, fatty acid conjugation, and fusion with albumin or Fc regions to enhance their therapeutic utility. The introduction of tirzepatide, which targets both GLP-1 and GIP receptors, further expanded the potential for these peptides in managing obesity.

What the Research Found

The review examines four approved GLP-1 RAs—exenatide, liraglutide, dulaglutide, and semaglutide—and tirzepatide. Key findings include:

  • Pharmacokinetics: Structural modifications have led to minimal metabolism and renal excretion for these peptides, resulting in prolonged half-lives compared to native GLP-1.
  • Drug-Drug Interactions (DDIs): Clinically significant DDIs mediated by drug-metabolizing enzymes or transporters are rare. However, mechanism-of-action-mediated DDIs involving delayed gastric emptying have been noted but generally considered clinically insignificant.
  • Specific Drug Interactions: Significant changes in exposure were observed for oral contraceptives and levothyroxine with the use of tirzepatide and semaglutide, respectively.

What This Means for Peptide Users

Clinicians need to be aware that while structural modifications have greatly improved the efficacy and convenience of GLP-1 RAs by extending their half-lives, they may also introduce new risks. For instance, patients taking oral contraceptives or levothyroxine should be closely monitored when using tirzepatide or semaglutide due to potential changes in drug exposure.

Limitations and Caveats

The review highlights several limitations:

  • Lack of Clinical Data: There is a dearth of clinical data on DDIs mediated by drug-metabolizing enzymes and transporters.
  • Volume of Distribution and Clearance Alterations: Further research is needed to understand how other mechanisms of action, such as changes in fat mass or cytochrome P450 activity, affect the pharmacokinetics of these peptides.

How This Compares to Previous Research

Previous studies have focused on individual GLP-1 RAs but lacked a comprehensive review that includes both pharmacokinetic profiles and DDIs. This study provides a consolidated view, making it easier for clinicians to understand the broader implications of using these therapies.

Our Analysis

PeptideVault's analysis suggests that while this review offers valuable insights into the current state of GLP-1 RAs and tirzepatide, there is still room for more detailed clinical studies on DDIs. The findings underscore the importance of personalized medicine approaches when prescribing these agents to ensure optimal safety and efficacy.

Key Takeaways

  • Structural Modifications: Enhance therapeutic utility but may increase adverse event risk.
  • DDI Monitoring: Clinicians should closely monitor patients using oral contraceptives or levothyroxine with tirzepatide or semaglutide.
  • Further Research Needed: Detailed clinical studies on DDIs and the impact of other mechanisms of action are essential.

Original Source

Citation: Min Jee Sun, Jo Seong Jun, Lee Sangyoung et al. (2025). A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.. Drug design, development and therapy. DOI: 10.2147/DDDT.S506957

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

편집자의 주석

Peptide Contacts 연구 팀은 복잡한 발견을 피테이드 커뮤니티에게 이해하기 쉬운 언어로 작성했습니다. 항상 원문의 전체 방법론과 데이터를 참조하십시오. GLP-1 receptor agonists에 대해 더 알아보기 연구 가이드.

참조 문헌

Min Jee Sun, Jo Seong Jun, Lee Sangyoung et al.. (2025). A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.. Drug design, development and therapy. https://doi.org/10.2147/DDDT.S506957

PubMed에서 전체 텍스트 확인하기

관련 논문

더 알아보기

이 내용은 교차 검토된 연구를 기반으로 교육 목적용으로 생성되었습니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 피테이드 기반 치료법을 사용하기 전에 항상 자격 있는 의료 전문가와 상담하십시오.